Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
06/2000
06/21/2000EP1009824A1 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-kappaB ACTIVATION
06/21/2000EP1009811A2 New tissue-specific calpaines, their production and their use
06/21/2000EP1009769A1 N-terminal modifications of rantes and methods of use
06/21/2000EP1009767A1 HUMAN DEFENSIN DEF-X, GENE AND DNAc, COMPOSITION CONTAINING SAME AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
06/21/2000EP1009760A2 Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
06/21/2000EP1009752A1 Novel molecules of the tango-77 related protein family and uses thereof
06/21/2000EP1009738A1 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
06/21/2000EP1009737A2 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
06/21/2000EP1009736A1 Malonic acid based matrix metalloproteinase inhibitors
06/21/2000EP1009426A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
06/21/2000EP1009413A2 Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
06/21/2000EP1009405A1 Pyrrolidine and piperidine modulators of chemokine receptor activity
06/21/2000EP1009402A4 Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
06/21/2000EP1009402A1 Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
06/21/2000EP1009393A2 Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience
06/21/2000EP1009387A1 Stabilized sustained release tramadol formulations
06/21/2000DE19858331A1 Tricyclische Stickstoffheterocyclen als PDE IV Inhibitoren Tricyclic nitrogen heterocycles as PDE IV inhibitors
06/21/2000CN1257545A Type II TGF-beta receptor/immunoglobulin constant region fusion proteins
06/21/2000CN1257538A Short peptides which selectively modulate the activity of serine/threonine kinases
06/21/2000CN1257507A Novel triptolide derivatives useful in the treatment of autoimmune diseases
06/21/2000CN1257506A Spiro-quinuclidine derivatives, their preparation and use
06/21/2000CN1257500A 9-azabicyclo (3,3,1) non-2-ene and nonane derivatives as cholinergic ligands at nicotinic ACH receptors
06/21/2000CN1257499A 8-Azabicyclo (3,2,1) oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACH receptors
06/21/2000CN1257489A Substituted benzopyran derivatives for the treatment of inflammation
06/21/2000CN1257485A Azacyclooctane and heptane derivatives, their preparation and usein therapy
06/21/2000CN1257481A Novel pyridine derivatives and pharmaceutical compositions containing them
06/21/2000CN1257421A Medicinal aerosol products
06/21/2000CN1053667C Inhibiting photodecomposition of 3-substituted-2-oxindoles
06/21/2000CN1053665C 2,4-diaryl-1,3-dithiolanes, 2,4-diaryl-1,3-dioxolanes, 2,4-diaryl-1,3-oxathiolanes derivant
06/21/2000CN1053584C Capsule for treating stubborn pain or numbness and preparation process thereof
06/20/2000US6077868 Administering to the animal an effective amount of a conjugated linoleic acid (cla) effective to reduce the activity of cyclooxygenase without gastric irritation side effect
06/20/2000US6077851 Quinoline derivatives
06/20/2000US6077850 Useful for treating cyclooxygenase-2 mediated disorders, such as inflammation and inflammation-related disorders
06/20/2000US6077845 As analgesic for alleviating pain
06/20/2000US6077833 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
06/20/2000US6077701 Ikkβ regulates transcription factors
06/20/2000CA2215659C Morphinan hydroxamic acid compounds
06/20/2000CA1341029C Peptidase inhibitors
06/15/2000WO2000034780A2 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
06/15/2000WO2000034516A1 Detection of rantes gene promotor polymorphisms
06/15/2000WO2000034477A2 Neuron-associated proteins
06/15/2000WO2000034474A2 Growth factor homolog zvegf3
06/15/2000WO2000034468A2 Muc-1 antagonists and methods of treating immune disorders
06/15/2000WO2000034447A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b
06/15/2000WO2000034338A2 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000WO2000034303A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
06/15/2000WO2000034295A2 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000WO2000034294A2 Tumor necrosis factor receptor homologue-1 ('trh1')
06/15/2000WO2000034281A1 Methotrexate derivatives
06/15/2000WO2000034278A1 Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient
06/15/2000WO2000034254A1 Novel compounds
06/15/2000WO2000034250A1 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
06/15/2000WO2000033888A2 Prodrug compounds and process for preparation thereof
06/15/2000WO2000033879A1 Method for the treatment of inflammation
06/15/2000WO2000033878A2 Stabilization of macrolides
06/15/2000WO2000033876A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/15/2000WO2000033842A1 Myt1 kinase inhibitors
06/15/2000WO2000033841A1 Myt1 kinase inhibitors
06/15/2000WO2000033838A1 Vitronectin receptor antagonist
06/15/2000WO2000033837A2 Myt1 kinase inhibitors
06/15/2000WO2000033824A2 Bioflavonoids, anthocyanins and phenolic compounds from cherries for inhibiting inflammation
06/15/2000WO2000033667A2 Bioflavonoids, anthocyanins and phenol compounds from cherries as antioxidants
06/15/2000WO2000015231A8 Adenosine a3 receptor modulators
06/15/2000WO2000013672A9 New solid dose form of nanoparticulate naproxen
06/15/2000WO2000012101A3 Use of selenium for treating patients suffering from systemic inflammatory response syndrome (sirs), and composition for implementing said treatment
06/15/2000WO2000006604A3 Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases
06/15/2000WO2000005254A3 Novel peptides for use in immunotherapy of autoimmune diseases
06/15/2000DE19857009A1 Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren Preparation with improved therapeutic index containing nucleotide synthesis
06/15/2000CA2732620A1 Crystalline form of 40-o-(2-hydroxy-ethyl) rapamycin and process for preparation thereof
06/15/2000CA2651609A1 Crystalline form of 40-o- (2-hydroxy-ethyl) rapamycin and process for preparation thereof
06/15/2000CA2363310A1 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
06/15/2000CA2354766A1 Prodrug compounds and process for preparation thereof
06/15/2000CA2354644A1 Muc-1 antagonists and methods of treating immune disorders
06/15/2000CA2354612A1 Tumor necrosis factor receptor homologue-1 ("trh1")
06/15/2000CA2354266A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/15/2000CA2354150A1 Detection of rantes gene promotor polymorphisms
06/15/2000CA2353839A1 Methotrexate derivatives
06/15/2000CA2353797A1 Neuron-associated proteins
06/15/2000CA2353415A1 Vitronectin receptor antagonist
06/15/2000CA2351452A1 Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
06/15/2000CA2351060A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000CA2351059A1 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000CA2319435A1 Triazolo derivatives and chemokine inhibitors containing the same as effective component
06/14/2000EP1007695A2 Rab proteins
06/14/2000EP1007678A1 Kringle1
06/14/2000EP1007645A1 Human serum inducible kinase (snk)
06/14/2000EP1007552A2 Diagnostics and therapy of epstein-barr virus in autoimmune disorders
06/14/2000EP1007547A1 Peptides comprising a t-cell epitope specific to collagen ii
06/14/2000EP1007545A2 Cyclopeptide derivatives as adhesion inhibitors
06/14/2000EP1007539A1 Secreted proteins and polynucleotides encoding them
06/14/2000EP1007537A1 Receptor protein designated 2f1
06/14/2000EP1007534A1 Bh3 interacting domain death agonist
06/14/2000EP1007520A1 2-aminopyridines containing fused ring substituents as nos inhibitors
06/14/2000EP1007512A1 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors
06/14/2000EP1007505A1 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
06/14/2000EP1007092A1 A process for inhibiting complement activation via the alternative pathway
06/14/2000EP1007090A1 Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
06/14/2000EP1007068A1 Process for preparing synthetic soil-extract materials and medicaments based thereon
06/14/2000EP1007067A1 Pharmaceutical compositions containing parthenium integrifolium or parts thereof or an extract or component thereof, the use of such plant material for preparing certain medicines, and a method of preparing an extract of parthenium integrifolium
06/14/2000EP1007047A1 Use of mizolastine for preparing a medicine for treating inflammation
1 ... 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 ... 1272